Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Alnylam Pharmaceuticals | Date: 2016-07-18

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.


Patent
Alnylam Pharmaceuticals | Date: 2016-10-28

The present invention relates to assays and methods for the detection of transthyretin and its isoforms. Specifically, the assays and methods of the present invention embrace liquid chromatography and mass spectrometry. The present invention also relates to unique peptides and peptide variants useful in the assays and methods.


The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.


Patent
Alnylam Pharmaceuticals | Date: 2017-03-15

The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R^(N)) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, - P(Z)(Z)0- nucleoside, -P(Z)(Z)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, P(Z)(Z)O-Linker-OP(Z)(Z)O-oligonucleotide, a nucleotide, an oligonucleotide, - P(Z)(Z)-formula(I), -P(Z)(Z)- or -Linker-R; R is L^(G), -Linker-L^(G), or has the structure shown below: L^(G) is independently for each occurence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R^(N) is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z, Z, Z and Z are each independently for each occurrence O or S.


Patent
Alnylam Pharmaceuticals | Date: 2016-10-25

Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.


Patent
Alnylam Pharmaceuticals | Date: 2016-12-30

The invention features compounds of formula V or XII: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.


Patent
Alnylam Pharmaceuticals | Date: 2016-08-18

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.


Patent
Alnylam Pharmaceuticals and Kumamoto University | Date: 2016-07-06

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.


Patent
Alnylam Pharmaceuticals | Date: 2017-01-06

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.


Patent
Alnylam Pharmaceuticals | Date: 2017-03-29

The present invention relates to RNAi agents, e.g., double- stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

Loading Alnylam Pharmaceuticals collaborators
Loading Alnylam Pharmaceuticals collaborators